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S U M M A R Y
Objective: The focus of this study was to ascertain the factors associated with 2009 pandemic inﬂuenza
H1N1 (pH1N1) infection during different phases of the epidemic.
Methods: In central Taiwan, 306 persons from households with schoolchildren were followed
sequentially and serum samples were taken at three sampling time-points starting in the fall of
2008, shortly after inﬂuenza vaccination. Participants who seroconverted between two consecutive
blood samplings were considered as having serological evidence of infection. A generalized estimation
equation (GEE) with a logistic link to account for household correlations was applied to identify factors
associated with pH1N1 infections during the pre-epidemic (April–June) and epidemic (September–
October) periods.
Results: The results showed that receiving an inactivated seasonal inﬂuenza vaccine (ISIV) and having a
hemagglutination inhibition assay (HI) titer of 40 or higher resulted in a signiﬁcantly lower likelihood of
pH1N1 infection during the pre-epidemic period only, for both children and adults (adjusted odds ratio
(OR) 0.3, 95% conﬁdence interval (CI) 0.12–0.9). Having a previous infection by pH1N1 with a baseline
titer of 20 or higher resulted in a signiﬁcantly lower likelihood of infection by pH1N1 during the epidemic
period (adjusted OR 0.06, 95% CI 0.02–0.16).
Conclusions: Our results provide the ﬁrst serological evidence to suggest a protection effect from
receiving an ISIV against pH1N1 infection only when the HI titer reaches 40 or higher during the pre-
epidemic period. This study gives an important insight into the control and intervention measures
required for preventing infections during future inﬂuenza epidemics.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
On April 24, 2009, a swine-origin H1N1 inﬂuenza virus (S-OIV)
emerged as a novel inﬂuenza A virus and caused widespread illness
in many countries worldwide, meeting the World Health
Organization (WHO) criteria for a pandemic. This is now termed
pandemic inﬂuenza H1N1 (pH1N1).1–3 Reports of antigenicity
distinct from that of seasonal human inﬂuenza A and differences in* Corresponding author. Tel.: +886 4 22075913; fax: +886 4 22075913.
E-mail address: hsieh@mail.cmu.edu.tw (Y.-H. Hsieh).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.05.012the pathogenicity of the virus in animal models increase concerns
for a pandemic with major public health consequences.4,5 At the
same time, the incidence of clinically severe cases appears to be
similar to that for seasonal ﬂu, with 5011 hospitalizations and 301
deaths in the USA between April 15 and July 24, according to US
Centers for Disease Control and Prevention (CDC) estimates.6 This
apparent contradiction highlights the need for better insights into
the risk and protection factors behind inﬂuenza virus infection.
As the pH1N1 virus spread around the world in late spring 2009,
at a time when well-matched pandemic vaccines were not
immediately available, the question of providing partial protection
with a seasonal inﬂuenza vaccine arose. However, the lack of fullses. Published by Elsevier Ltd. All rights reserved.
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vated seasonal inﬂuenza vaccines (ISIV) and for unvaccinated
individuals of various ages, resulted in inconsistent results when
the effectiveness of seasonal inﬂuenza vaccination in preventing
2009 pH1N1 morbidity in the general population was evaluated, as
previously published.7–10 As experts in various ﬁelds have called
for serological investigations to more accurately determine rates of
infection, the stored blood bank would be very useful in unveiling
the extent of ISIV protection in terms of basic research and public
health, which is the focus of our current study.
The government in Taiwan initiated a pandemic H1N1 clinical
surveillance system on April 29, and from that date on an increasing
number of probable cases was reported, especially after May 15,
which correlated with the ﬁrst laboratory-conﬁrmed imported
pH1N1 case on May 19. By the end of June, there were 61 travel-
related laboratory-conﬁrmed cases.11 The ﬁrst wave of 2009
pandemic H1N1 began around July 1, peaked in the last week of
August, and had subsided by the end of September. We utilized the
serum banks, initially collected to evaluate the effectiveness of the
ISIV, to determine the antibody level of seasonal inﬂuenza virus and
pH1N1 virus before and after the different phases of the epidemic as
the baseline and marker of infection, within a household study
design. Our aim was to compare the risk and protection factors
associated with infection during different phases of the epidemic.
2. Materials and methods
2.1. Study sites and serum collection
Taiwan has a population of over 23 million. Since 2007, all
schoolchildren in grades 1–4 in Taiwan have received a free
inﬂuenza vaccination (ISIV) annually from the government. In
order to evaluate vaccine efﬁcacy, students from two elementary
schools located in the urban Taichung City and four schools in the
rural Nantou County in central Taiwan were recruited into a 3-year
study starting in the fall of 2008. Taichung City is the largest urban
city in central Taiwan with a population of more than 1 million and
a highly developed socio-economic structure. The two schools
selected were located respectively in the north and central districts
of the city, with approximately 140 000 total residents. Nearby
Nantou County, with a total land size approximately 25 times
larger than that of Taipei City, is the second largest county and the
only landlocked county on the island of Taiwan, with a population
of over 500 000, and is comparatively less developed socio-
economically. The four schools in Nantou County were selected
purposely from four different administrative districts in the
county, namely Nantou City and Tsaotun Township each with
around 100 000 residents, and the rural townships of Mingjian and
Guoshing with around 40 000 and 20 000 residents, respectively.
Family members of the students were also recruited into the
study to further determine the effectiveness of seasonal inﬂuenza
vaccine in preventing household transmissions. The study protocol
based on clinical and laboratory data was established and at least
two blood samples were drawn from the study subjects, before and
after an inﬂuenza season. In the fall of 2008, 454 persons from 147
households were recruited into the study. Among them, 306 persons
belonging to 104 households remained in the study in 2009 and
underwent all three samplings required for the analysis in this
report.
To evaluate the kinetic changes in antibody responses against
the inﬂuenza H1N1 virus of seasonal vaccine, wild-type, and the
2009 pH1N1 strain, only 306 study subjects who had three
complete sequential blood samples taken were selected from the
serum bank. The ﬁrst blood samples were taken in the fall of 2008,
about 2 to 3 weeks after inﬂuenza vaccination (referred to
henceforth as the baseline titer); the second blood samples weretaken in April–June of 2009 (referred to henceforth as the pre-
epidemic period) after the 2008–09 inﬂuenza season; and the third
samples were taken in September–October of 2009 (referred to
henceforth as the epidemic period) before vaccination with both
the 2009–10 seasonal and the 2009 pandemic inﬂuenza strains.
Venous blood was taken in 5- to 10-ml plain tubes and the serum
was collected after centrifugation and stored at 20 8C until use.
All subjects gave informed consent to study participation and the
study was approved by the Medical Ethics Committee of the China
Medical University.
2.2. Data collection
Two questionnaires were conducted by trained interviewers and
were used to collect basic demographic and social contact
information and whether a seasonal inﬂuenza vaccination had
been received in the past 2 years. Information regarding underlying
diseases, including cardiovascular disease, hypertension, or diabetes
mellitus, was also obtained from the adults in the family. Clinical
symptoms reviews were carried out using a standardized question-
naire every 2 weeks via telephone interview. Participants were
asked to report any newly experienced febrile respiratory symp-
toms, including fever, sore throats, and headaches during the 2008–
09 inﬂuenza season. However, the clinical information during the
summer season was only obtained retrospectively in December and
substantial recall error was expected.
2.3. Laboratory methods
Antibody titers were measured by a hemagglutination inhibi-
tion (HI) assay following the standard protocol of the WHO.12 The
virus strain used was originally isolated from a patient infected by
S-OIV H1N1, which is antigenically and genetically closely related
to A/California/07/2009.
To evaluate cross-reactivity, a vaccine strain of H1N1 (A/
Brisbane/59/2007) and a wild-type strain that represented more
than 80% of the H1N1 circulating during the 2008–09 inﬂuenza
season (A/Taiwan/606/2008) were also used. All viruses used in
this study were cultured from Madin–Darby canine kidney (MDCK)
cells and centrifuged at 1600 rpm, 4 8C to remove cell debris. For
the HI assay, serum samples were pre-treated with receptor
destroying enzyme and titrated in two-fold dilutions in phosphate-
buffered saline (PBS) with an initial dilution of 1:10 and a ﬁnal
dilution of 1:1024. Titers were expressed as the reciprocal of the
highest dilution of serum at which hemagglutination was
prevented. A four-fold or greater increase in HI titer between
the two consecutive serological samples was deﬁned as evidence of
H1N1 seroconversion. Samples that were negative by HI were
assigned a titer of 1:5 for computational purposes in obtaining a
four-fold increase of HI titers.
The HI titers against the individual virus strains used in this
study were determined for pH1N1, the seasonal inﬂuenza H1N1
vaccine strain (sH1N1 v), and wild-type strain (sH1N1w). Parti-
cipants who seroconverted between two consecutive blood
samplings (either from the ﬁrst to the second sample, or from
the second to the third sample) were considered to have
serological evidence of infection during the pre-epidemic or
epidemic period, respectively. Geometric mean titers (GMTs) were
used to avoid skewed data distribution through a log transforma-
tion and were estimated by assigning a value of 5 for titers lower
than 10 and a value of 2560 for titers of 2560 or higher.
2.4. Statistical analysis
As the study design was based on the prospective family cohort
and the infection status may be non-independent within a
Table 1
Univariate analysis of demographic factors associated with seroconversion during the pre-epidemic (April–June) and epidemic (September–October) periods
Pre-epidemic period (April–June) Epidemic period (September–October)
Seroconversion Seroconversion
No./total % (95% CI) OR (95% CI) p-Value No./total % (95% CI) OR (95% CI) p-Value
Age (years)
5–18 26/143 18.2 (12–25) 1 62/143 43.4 (35–52) 1
19–60 35/147 23.8 (17–31) 1.41 (0.88–2.24) 0.15 65/147 44.2 (36–52) 1.04 (0.67–1.60) 0.88
>60 5/16 31.3 (9–54) 2.05 (0.64–6.52) 0.23 9/16 56.3 (32–81) 1.68 (0.53–5.29) 0.38
Area of residence
Urban 17/101 16.8 (10–24) 0.64 (0.26–1.62) 0.35 55/101 54.5 (45–64) 1.83 (1.03–3.24) 0.04
Rural 49/205 23.9 (18–30) 1 81/205 39.5 (33–46) 1
Gender
Female 35/173 20.2 (14–26) 1 82/173 47.4 (40–55) 1
Male 31/133 23.3 (16–30) 1.20 (0.73–1.97) 0.48 54/133 40.6 (32–49) 0.76 (0.48–1.19) 0.23
Number of family members
<4 8/33 24.2 (10–39) 1 11/33 33.3 (17–49) 1
4 58/273 21.3 (16–26) 0.84 (0.23–3.08) 0.80 125/273 45.8 (40–52) 1.69 (0.65–4.38) 0.28
Size of the housing areaa
<30 17/66 25.8 (15–36) 1 28/66 42.4 (30–54) 1
30 48/238 20.2 (15–25) 0.73 (0.29–1.84) 0.50 107/238 45.0 (39–51) 1.11 (0.57–2.15) 0.76
Personal bedroom
No 51/218 23.4 (18–29) 1 96/218 44.0 (37–51) 1
Yes 15/79 19.0 (10–28) 0.77 (0.38–1.54) 0.46 33/79 41.8 (31–53) 0.91 (0.52–1.59) 0.74
Number of household children aged 12 years
<3 51/240 21.3 (16–26) 1 106/240 44.2 (38–50) 1
3 15/66 22.7 (13–33) 1.09 (0.43–2.78) 0.86 30/66 45.5 (33–58) 1.05 (0.50–2.21) 0.89
OR, odds ratio; CI, conﬁdence interval.
a Size of the housing area was measured in pin (local area unit); 1 pin is equivalent to approximately 3.3 square meters.
Figure 1. Geometric mean titers of seasonal H1N1 vaccine and wild-type strains
and 2009 pandemic H1N1 virus measured by the hemagglutination inhibition assay
from sequential sera collected at the different sampling times.
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model with logistic link to detect the potential risk variables. The
potential risk variables, including demographic data, household
and social contact information, vaccination status, and baseline
antibody titer against individual subtypes, as well as household
contacts (classiﬁed according to the seroconversion status of
individuals in the household: (1) any other household member
seroconverted, (2) any other household member aged less than 18
years seroconverted, (3) any other household member aged older
than 18 years seroconverted) were ﬁrst studied using univariate
analysis. To further characterize the factors associated with
seroconversion of pH1N1 among the different age groups,
multivariate analysis based on the signiﬁcant risk factors identiﬁed
in the univariate analysis and confounding variables (age, gender,
area of residence, vaccination records, and baseline vaccine strain
titer) was performed separately for the group of schoolchildren
aged 5–18 years and the group of adults aged >19 years. The
subjects aged >60 years were combined with the adult age group
because of the small sample size. Stepwise logistic regression with
backward selection was applied, wherein variables that did not
improve the model ﬁt at p < 0.10 were discarded but confounding
variables were always forced into the model. In the univariate and
ﬁnal multivariate analysis, odds ratios (ORs) with asymptotic Wald
95% conﬁdence intervals (CIs) and two-sided p-values were
calculated. SAS statistical package version 9.2 (SAS Institute Inc.,
Cary, NC, USA) was used for the analysis, and statistical signiﬁcance
was set at the 0.05 level.
3. Results
A total of 306 subjects from 104 different families were
included in this study for the evaluation of risk/protection factors.
The subjects included 143 schoolchildren and their siblings aged
between 5 and 18 years, 147 adults aged between 19 and 60 years,
and 16 people aged >60 years. Figure 1 shows the GMT against
pH1N1, the seasonal inﬂuenza H1N1 vaccine strain (sH1N1 v), and
wild-type strain (sH1N1w) from the sera collected during the three
sampling periods. A sequential increase in GMT of pH1N1 through
three different sampling periods was observed along with anincrease in the titer of sH1N1w from the ﬁrst to the second
sampling period; however, GMT against sH1N1 v decreased from
the ﬁrst to the second sampling period.
Table 1 shows the results of the univariate analysis of
demographic factors associated with seroconversion during the
pre-epidemic period (April–June) and the epidemic period (July–
October). Of the school-aged children (5–18 years), 18.2% showed
seroconversion during the pre-epidemic period, and the number
increased to 43.4% during the epidemic period. Similarly, 23.8% in
the adult group (19–60 years) and 31.3% in the older group (>60
years) showed seroconversion during the pre-epidemic period,
which increased to 44.2% and 56.3%, respectively, during the
epidemic period. Those living in rural areas showed higher
seroconversion (23.9%) compared to those living in urban areas
(16.8%) during the pre-epidemic period, although this difference
was not statistically signiﬁcant. However, the opposite situation
was observed during the epidemic period, with signiﬁcantly higher
seroconversion for subjects living in urban areas (54.5%) than for
Table 2
Univariate analysis of vaccine-related factors associated with seroconversion during the pre-epidemic (April–June) and epidemic (September–October) periods
Pre-epidemic period (April–June) Epidemic period (September–October)
Seroconversion Seroconversion
No./total % (95% CI) OR (95% CI) p-Value No./total % (95% CI) OR (95% CI) p-Value
Vaccination 2007–08
No 52/234 22.2 (17–28) 1 102/234 43.6 (37–50) 1
Yes 14/71 19.7 (10–29) 0.86 (0.47–1.58) 0.63 33/71 46.5 (35–58) 1.12 (0.64–1.98) 0.69
Vaccination 2008–09
No 47/200 23.5 (18–29) 1 89/200 44.5 (38–51) 1
Yes 19/106 17.9 (11–25) 0.71 (0.38–1.31) 0.28 47/106 44.3 (35–54) 0.99 (0.60–1.65) 0.98
Baseline sH1N1wb HI titera
<40 22/90 24.4 (16–33) 1 41/88 46.6 (36–57) 1
40 44/216 20.4 (15–26) 0.79 (0.44–1.41) 0.43 95/218 43.6 (37–50) 0.89 (0.56–1.40) 0.60
Baseline sH1N1vc HI titer
<40 46/177 26.0 (20–32) 1 95/208 45.7 (39–52) 1
40 20/129 15.5 (9–22) 0.52 (0.32–0.86) 0.01 41/98 41.8 (32–52) 0.86 (0.51–1.43) 0.55
Baseline pandemic H1N1 titer
<20 65/303 21.5 (17–26) 1 127/224 56.7 (50–63) 1
20 1/3 33.3 (0–87) 1.83 (0.17–19.51) 0.62 9/82 11.0 (4–18) 0.09 (0.04–0.20) <0.0001
Four-fold increase of sH1N1v or sH1N1w
No 114/236 48.3 (42–55) 1
Yes 22/70 31.4 (21–42) 0.49 (0.28–0.87) 0.02
Other household members with seroconversiond
No 14/215 6.5 (3–10) 1 36/110 32.7 (24–41) 1
Yes 52/91 57.1 (47–67) 19.14 (7.23–50.70) <0.0001 100/196 51.0 (44–58) 2.14 (1.04–4.39) 0.04
OR, odds ratio; CI, conﬁdence interval.
a HI titer refers to the antibody titers measured by a hemagglutination inhibition (HI) assay.
b sH1N1w refers to the seasonal H1N1 virus wild-type strain (A/Taiwan/606/2008) used for the HI assay.
c sH1N1 v refers to the seasonal H1N1 virus vaccine strain (A/Brisbane/59/2007) used for the HI assay.
d Other household members with seroconversion: at least one other household member with seroconversion vs. no one else in the household with seroconversion.
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was statistically signiﬁcant. In our study, males and females
showed similar seroconversion rates in both the pre-epidemic and
epidemic periods (23.3% vs. 20.2% pre-epidemic and 40.6% vs.
47.4% epidemic).
Moreover, the proportions of seroconversion were approxi-
mately the same, without any statistical signiﬁcance, for factors
associated with family contacts, including the number of
household members, the size of the household area, the number
of children younger than 12 years, and whether or not each
household member has a personal bedroom.
Since seroconversion can be considered as an indicator of the
variation in risk of infection, the effect of seasonal inﬂuenza
vaccination on protection from pH1N1 infection was studied.
The results are summarized in Table 2. Recipients of seasonal
inﬂuenza vaccines in the 2007–08 or 2008–09 seasons were less
likely to exhibit seroconversion of pH1N1, although this was
without statistical signiﬁcance. Interestingly, among 129 sub-
jects with an sH1N1 v baseline titer of 40 or higher, 15.5%
seroconverted to pH1N1 during the pre-epidemic period,
compared to 26.0% among those with a baseline titer lower
than 40; this showed signiﬁcant protection (OR 0.52, 95% CI
0.32–0.86). A similar protection effect was not observed for the
same baseline titer of pH1N1 or sH1N1w during the pre-
epidemic period. Conversely, baseline H1N1 titers of 40 or
higher against either sH1N1 v or sH1N1w were not statistically
associated with the seroconversion of pH1N1 during the
epidemic period (OR 0.86 and 0.89, respectively). However,
31.4% with a four-fold increase in HI titers against either
sH1N1 v or sH1N1w showed seroconversion to pH1N1, com-
pared to 48.3% without a four-fold increase who showed
seroconversion (OR 0.49, 95% CI 0.28–0.87). Meanwhile, those
previously infected by pH1N1 with a baseline HI titer of 20 or
higher showed strong protection against infection by pH1N1
during the epidemic period (OR 0.09, 95% CI 0.04–0.2). In both
the pre-epidemic and epidemic periods, there was an increased
risk of pH1N1 infection if another family member showedseroconversion of pH1N1 (OR 19.14, 95% CI 7.23–50.7 for the
pre-epidemic period and OR 2.14, 95% CI 1.04–4.39 for the
epidemic period).
The results of multivariate analysis are shown in Table 3. We
observed a higher likelihood of infection during the pre-epidemic
period if other household members had seroconverted (adjusted
OR 25.76, 95% CI 9.64–68.81), but no such association character-
ized the epidemic period. Since vaccination with ISIV is highly
associated with HI titers of 40 or higher against sH1N1 v, the
interaction between these two factors was taken into consider-
ation in the multivariate analysis. The results showed that
receiving a vaccination along with having an HI titer of 40 or
higher resulted in a signiﬁcantly lower likelihood of pH1N1
infection during the pre-epidemic period (adjusted OR 0.33, 95% CI
0.12–0.90). This protection effect was not observed during the
epidemic period; instead, having been previously infected by
pH1N1 and having a baseline titer of 20 or higher showed a
signiﬁcantly lower likelihood of pH1N1 infection (adjusted OR
0.06, 95% CI 0.02–0.16).
In order to understand whether children mediate a higher risk
of household transmission of inﬂuenza virus, we further charac-
terized the factors associated with seroconversion of pH1N1 in the
different age groups; multivariate analysis was performed
separately for the schoolchildren aged 5–18 years and the adults
aged >19 years. Subjects aged >60 years were combined with the
adult age group because of the small sample size. The results from
the analysis in the adult age group are shown in Table 4; the results
for the schoolchildren age group are not represented in a table as
they were found to be similar to the results from the overall cohort.
Having a baseline HI titer of 40 or higher for sH1N1 v was still
strongly associated with a lower likelihood of pH1N1 infection
during the pre-epidemic period in the adult age group (adjusted OR
0.32, 95% CI 0.11–0.91). This effect again was not observed during
the epidemic period, and the conditions instead were having a
previous infection and a baseline titer of 20 or higher to pH1N1
(adjusted OR 0.02, 95% CI 0.00–0.18). Interestingly, living with
another adult household member with seroconversion (adjusted
Table 3
Multivariate analysis for factors associated with seroconversion (four-fold increase) during the pre-epidemic and epidemic periods for all subjects (N = 305a)
Variable Pre-epidemic period (April–June) Epidemic period (September–October)
beta SE p-Value OR (95% CI) beta SE p-Value OR (95% CI)
Age, years >18 vs. 5–18 0.68 0.44 0.12 1.96 (0.83–4.62) 0.077 0.33 0.81 1.08 (0.57–2.04)
Gender Male vs. female 0.35 0.40 0.38 1.42 (0.65–3.08) 0.313 0.27 0.25 0.73 (0.43–1.24)
Area of residence Urban vs. rural 0.47 0.36 0.19 0.62 (0.31–1.27) 0.544 0.28 0.05 1.72 (1.00–2.97)
Vaccination 2007–08 Yes vs. no 0.55 0.48 0.25 1.73 (0.68–4.39) 0.303 0.38 0.43 1.35 (0.64–2.87)
Vaccination 2008–09
+ baseline sH1N1vc HI titer
Non-vaccinated, HI <40b Referent group 1.00 Referent group 1.00
Non-vaccinated, HI 40 0.86 0.69 0.21 0.42 (0.11–1.63) 0.456 0.49 0.35 0.63 (0.24–1.66)
Vaccinated, HI <40 0.005 0.47 0.99 1.01 (0.40–2.53) 0.292 0.42 0.48 0.75 (0.33–1.69)
Vaccinated, HI 40 1.12 0.52 0.03 0.33 (0.12–0.90) 0.356 0.52 0.49 0.70 (0.25–1.94)
Baseline pandemic H1N1 HI
titer (2nd sampling)
20 vs. <20 –e –e –e –e 2.829 0.50 <0.0001 0.06 (0.02–0.16)
Other household members
with seroconversiond
Yes vs. no 3.25 0.50 <0.0001 25.76 (9.64–68.81) 0.407 0.38 0.28 1.50 (0.71–3.17)
SE, standard error of beta estimate; OR, odds ratio; CI, conﬁdence interval.
a One observation missing for vaccination in 2007–08.
b HI titer refers to the antibody titers measured by a hemagglutination inhibition (HI) assay.
c sH1N1 v refers to the seasonal H1N1 virus vaccine strain (A/Brisbane/59/2007) used for HI assay.
d Other household members with seroconversion: at least one other household member with seroconversion vs. no one else in the household with seroconversion.
e Not included in the multivariate model because of insufﬁcient data.
Table 4
Multivariate analysis for factors associated with seroconversion (four-fold increase) during the pre-epidemic and epidemic periods for adult subjects (N = 156a)
Variable Pre-epidemic period (April–June) Epidemic period (September–October)
beta SE p-Value OR (95% CI) beta SE p-Value OR (95% CI)
Gender Male vs. female 0.76 0.45 0.10 2.13 (0.88–5.20) 0.09 0.40 0.81 1.10 (0.51–2.38)
Area of residence Urban vs. rural 0.34 0.44 0.44 0.71 (0.30–1.69) 0.40 0.38 0.29 1.50 (0.71–3.17)
Vaccination 2007–08 Yes vs. no 0.88 1.16 0.45 0.42 (0.04–4.05) 1.66 1.08 0.12 0.19 (0.02–1.58)
Vaccination 2008–09 Yes vs. no 0.13 0.74 0.86 1.14 (0.27–4.82) 0.28 0.88 0.75 1.33 (0.24–7.48)
Baseline sH1N1v HI titerb 40 vs. <40 1.15 0.54 0.03 0.32 (0.11–0.91) 0.04 0.65 0.95 0.96 (0.27–3.46)
Seroconversion of
sH1N1v or sH1N1wc Yes vs. no –f –f –f –f 0.69 0.48 0.15 0.50 (0.20–1.29)
Baseline pandemic H1N1
HI titer (2nd sampling)
20 vs. <20 –f –f –f –f 3.85 1.09 <0.001 0.02 (0.00–0.18)
Other household adults
(age >18 years) with
seroconversiond
Yes vs. no 2.20 0.66 0.001 9.04 (2.46–33.22) 0.57 0.49 0.24 1.77 (0.68–4.60)
Having underlying diseasese Yes vs. no 1.38 0.56 0.01 3.97 (1.34–11.80) 1.38 0.66 0.04 3.97 (1.08–14.55)
SE, standard error of beta estimate; OR, odds ratio; CI, conﬁdence interval.
a Nine observations missing for underlying diseases.
b HI titer refers to the antibody titers measured by a hemagglutination inhibition (HI) assay.
c Seroconversion of sH1N1 v or sH1N1w: having four-fold increase in HI titer against either the seasonal H1N1 virus vaccine strain (A/Brisbane/59/2007) or the seasonal
H1N1 wild-type stain (A/Taiwan/606/2008) from the ﬁrst and second follow-up samples.
d Other household members with seroconversion: at least one other household member aged older than 18 years with seroconversion vs. no one else in the household with
seroconversion.
e Underlying diseases refers to having one of the following three diseases: cardiovascular disease, hypertension, or diabetes mellitus.
f Not included in the multivariate model because of insufﬁcient data.
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(adjusted OR 3.97, 95% CI 1.34–11.80), resulted in a higher risk
of infection by pH1N1 in the pre-epidemic period. Meanwhile,
having underlying diseases also resulted in a higher likelihood of
infection in the adult age group during the epidemic period
(adjusted OR 3.91, 95% CI 1.08–14.55).Table 5
Multivariate analysis for factors of household children associated with seroconversion
Variable 
Age, years >18 vs. 5–18 
Gender Male vs. female 
Area of residence Urban vs. rural 
Vaccination 2007–08 Yes vs. no 
Vaccination 2008–09 Yes vs. no 
Baseline A/H1N1 vaccine strain HI titerb 40 vs. <40 
Other household children (age 18 years)
with seroconversion
Yes vs. no 
SE, standard error of beta estimate; OR, odds ratio; CI, conﬁdence interval.
a 1 observation missing for vaccination 2007–2008.
b HI titer refers to the antibody titers measured by a hemagglutination inhibition (HDifferent methods were also compared in this study. In order to
understand whether children mediate a higher risk of household
transmission of inﬂuenza virus, we further classiﬁed other
household members with seroconversion into groups of school-
children (<18 years old) and adults (>18 years old). Results
showed that having children with seroconversion in the household (four-fold increase) during the pre-epidemic period for all subjects (N = 305a)
beta SE p-Value OR (95% CI)
0.14 0.43 0.74 1.15 (0.50–2.67)
0.23 0.32 0.47 1.26 (0.67–2.36)
0.46 0.34 0.18 0.63 (0.32–1.24)
0.03 0.59 0.96 1.03 (0.32–3.30)
0.27 0.72 0.71 1.31 (0.32–5.37)
1.02 0.50 0.04 0.36 (0.14–0.95)
3.24 0.49 <0.0001 25.58 (9.77–66.96)
I) assay.
Table 6
Multivariate analysis for factors of household adults associated with seroconversion (four-fold increase) during the pre-epidemic period for all subjects (N = 305a)
Variable beta SE p-Value OR (95% CI)
Age, years >18 vs. 5–18 0.81 0.38 0.03 2.24 (1.07–4.68)
Gender Male vs. female 0.26 0.38 0.50 1.30 (0.61–2.75)
Area of residence Urban vs. rural 0.53 0.40 0.18 0.59 (0.27–1.28)
Vaccination 2007–08 Yes vs. no 0.88 0.38 0.02 2.40 (1.15–5.02)
Vaccination 2008–09 Yes vs. no 0.33 0.37 0.37 0.72 (0.35–1.49)
Baseline A/H1N1 vaccine strain HI titerb 40 vs. <40 0.85 0.31 0.006 0.43 (0.24–0.78)
Other household adults (age >18 years) with seroconversion Yes vs. no 2.67 0.49 <0.0001 14.41 (5.52–37.66)
SE, standard error of beta estimate; OR, odds ratio; CI, conﬁdence interval.
a 1 observation missing for vaccination 2007–2008.
b HI titer refers to the antibody titers measured by a hemagglutination inhibition (HI) assay.
Table 7
Multivariate analysis for factors associated with seroconversion (four-fold increase) during the epidemic period
Variable Total (N = 305)a Age >18 years (N = 156)b
beta SE p-Value OR (95% CI) beta SE p-Value OR (95% CI)
Age, years >18 vs. 5–18 0.03 0.31 0.92 1.03 (0.56–1.90) – – – –
Gender Male vs. female 0.40 0.26 0.11 0.67 (0.41–1.10) 0.26 0.38 0.49 0.77 (0.37–1.62)
Area of residence Urban vs. rural 0.65 0.27 0.02 1.91 (1.12–3.27) 0.45 0.34 0.19 1.56 (0.81–3.03)
Vaccination 2007–08 Yes vs. no 0.40 0.38 0.30 1.49 (0.71–3.12) 0.59 0.87 0.50 0.55 (0.10–3.02)
Vaccination 2008–09 Yes vs. no 0.15 0.35 0.67 0.86 (0.44–1.70) 0.29 0.82 0.72 1.34 (0.27–6.63)
Baseline A/H1N1 vaccine strain HI titerc 40 vs. <40 0.14 0.36 0.69 0.87 (0.43–1.74) 0.14 0.62 0.83 1.15 (0.34–3.88)
Four-fold increase of seasonal H1N1
(vaccine or wild-type strain)
Yes vs. no 0.80 0.30 0.008 0.45 (0.25–0.81) 1.04 0.43 0.02 0.35 (0.15–0.81)
Other household members
with seroconversion
Yes vs. no 0.74 0.37 0.05 2.10 (1.01–4.33) – – – –
Other household adults
(age >18 years) with seroconversion
Yes vs. no – – – – 1.17 0.45 0.01 3.23 (1.33–7.85)
SE, standard error of beta estimate; OR, odds ratio; CI, conﬁdence interval.
a 1 observation missing for vaccination 2007–2008.
b 9 observations missing for underlying diseases.
c HI titer refers to the antibody titers measured by a hemagglutination inhibition (HI) assay.
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9.77–66.96), compared to adults with seroconversion in the
household (adjusted OR 14.41, 95% CI 5.52–37.66), with statistical
signiﬁcance in both models (Tables 5 and 6). Moreover, having a
four-fold increase in the HI titer against sH1N1 v or sH1N1w
during the pre-epidemic period resulted in a lower likelihood of
infection by pH1N1 during the epidemic period, with OR of 0.45
(95% CI 0.25–0.81) (Table 7).
4. Discussion
To the best of our knowledge, this is the ﬁrst cohort study
designed to distinguish the effect of receiving an ISIV on protection
against pH1N1 infection using serological assays. Our study shows
that the risk of infection by pH1N1 was 0.33-fold lower (95% CI
0.12–0.90) among vaccine recipients if the baseline HI titer was 40
or higher, compared to those without vaccinations and a baseline
titer below 40, during the pre-epidemic period in April–June.
However, the protection effect of the baseline HI titer by
vaccination was not signiﬁcant during the epidemic period due
to the waning of antibody induced by vaccination after 6 months.
Instead, the risk of infection by pH1N1 among those who had
previously been infected by pH1N1 (pH1N1 baseline titer of 20 or
higher during the second sampling period) was 16.7-fold lower
than in those who had not been previously infected (95% CI 0.02–
0.16). Having another household member with seroconversion or
having underlying diseases were shown to be important risk
factors for infection by pH1N1, similar to the results of previous
studies.13,14
The assessment of the potential risk and protection factors for
inﬂuenza virus infection could be affected by the ascertainment bias
of case status. Early data based on a frequency-matched case–
control study from Mexico revealed some protection against pH1N1infection, particularly severe forms of the disease, among ISIV
recipients, although it was unclear whether these observations were
affected by biases in case ascertainment.7,9 Classifying the case
status by the appearance of respiratory symptoms could lead to
misclassiﬁcation because of the substantial proportion of subclinical
infections.15–17 The detection of virus in nasopharyngeal and
oropharyngeal specimens from those with symptoms resembling
infection could be affected by the sensitivity and speciﬁcity of the
polymerase chain reaction (PCR) assay.18,19 Using serological
cohorts is one of the best ways to differentiate infection status
associated with risk and protection factors. The study conducted by
Chen et al. failed to demonstrate a protection effect of receiving ISIV
against pH1N1 infection, without measuring the HI titer against
sH1N1 v and sH1N1w.13 Also, rather surprisingly, the Canadian
sentinel study showed that receiving an ISIV in the previous season
appeared to increase the risk of pH1N1 illness, even after adjustment
for co-morbidities, age, and geography.10 Again, their study failed to
measure the HI titer against different strains of H1N1. The causal-
inference relationship was established in our study through the
prospective cohort design, by measuring the kinetic changes of
antibody titer against different H1N1 strains, which emphasizes the
valuable information obtained from the serum bank.
Previous studies have suggested that household transmission
with children presents a higher risk of pH1N1 infection.20,21
Interestingly, by using other household members older than 18
years of age with seroconversion as a co-variable (Tables 5 and 6),
signiﬁcant factors included having an sH1N1 v baseline titer of 40
or higher and being older than 18 years and the recipient of the
2007–08 seasonal vaccine during the pre-epidemic period. Having
a four-fold increase in the HI titer against sH1N1 v or sH1N1w
during the pre-epidemic period also resulted in a lower likelihood
of pH1N1 infection during the epidemic period, as previously
published22 (Table 7). It is tempting to speculate on the
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ISIV or the infection by sH1N1w in terms of the disease severity
and death rate of S-OIV as compared with seasonal human H1N1
inﬂuenza virus. It was initially feared that the current S-OIV would
be much more lethal than seasonal H1N1 inﬂuenza. In fact,
although S-OIV isolates were consistently found to replicate better
in the lung tissue of animal models,23–25 the potential pathogenic
nature of S-OIV is not supported by the currently available data.
The data suggest that there are large numbers of suspected
infections, but a disproportionately low number of deaths
associated with S-OIV in the USA. We propose that the divergence
in disease severity observed in most animal studies and found in
the human population could be due to the contribution of a pre-
existing T-cell-mediated immunity that lessens disease severity, as
suggested in previous studies.26–29
In conclusion, our study demonstrated that the risk of pH1N1
infection was associated with seroconversion in another family
member, especially children, and the presence of underlying
diseases. The target population for the pandemic inﬂuenza vaccine
should be either schoolchildren, which would stop transmission, or
those in the adult age group with underlying diseases. Focusing on
these groups would reduce the morbidity and mortality in the
general population. At the same time, our study conﬁrmed that
partial protection from receiving an ISIV occurred only if there was
an HI titer of 40 or higher after vaccination. Although the
household study design might limit the applicability of our study
to the general population, the results obtained from this current
study may assist in the implementation of intervention and control
strategies in future inﬂuenza virus pandemics.
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